RESECT: A Randomised Controlled Trial of Audit and Feedback in Non-muscle-invasive Bladder Cancer Surgery.
AuteursGallagher K, MacLennan S, Bhatt N, Clement K, Zimmermann E, Khadhouri S, Kulkarni M, Gaba F, Anbarasan T, Asif A, Light A, Ng A, Chan VW, Nathan A, Cooper D, Aucott L, Sakthivel D, Akand M, Piazza P, Marcq G, O'Brien T, Nielsen M, Giudice FD, Simpson K, Orecchia L, Teixeira B, Dawam D, Geisenhoff A, Hill G, Fukuokaya W, Hidalgo BG, El-Hajj A, Elgamal M, Fanshawe J, Wang B, Lee T, Manecksha R, McCann C, Rivas JG, Arda E, Elhadi M, Rossi S, Teoh JY, Mariappan P, Kasivisvanathan V
Postmenopausal Osteoporosis: From Molecular Pathways to Therapeutic Targets-A Mechanism-to-Practice Framework Integrating Pharmacotherapy, Fall Prevention, and Adherence into Patient-Centered Care.
AuteursPansieri J, Figiel S, Menassa D, Ricigliano VAG, Seferoglu M, Borrelli S, Szejko N, Samadzadeh S, Boldrini V, Zarco L, Correa-Díaz EP, Pozzilli V, Marenna S, Carnero Contentti E, Koc ER, Dalla Costa G, Casallas-Vanegas A, Bakirtzis C, Gluscevic S, Tunç A, Gomez Figueroa E
Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study.
AuteursBhave M, Jhaveri KL, Kaufman PA, Aftimos P, Lombard J, Giridhar KV, Im SA, Ma CX, Lee KT, Kim SB, Sohn J, Li Y, Yuen E, Estrem ST, Nguyen B, Makena MR, Ismail-Khan R, Beeram M
